摘要:目的 观察长期无创正压通气(NIPPV)对稳定期严重慢性阻塞性肺疾病(COPD)合并呼吸衰竭患者临床疗效及血清基质金属蛋白酶9(MMP-9)的影响.方法 选择80例处于稳定期的严重COPD合并呼吸衰竭患者,按其能否耐受并接受长期NIPPV治疗分为实验组和对照组,两组患者均给予吸氧、口服茶碱缓释片、吸入噻托溴铵等治疗,实验组在此基础上加用双水平NIPPV治疗1年.观察两组患者治疗前后圣乔治呼吸问卷评分(SGRQ评分)、呼吸困难评分(MMRC评分)、六分钟行走距离(6-MWD)、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、第1秒用力呼气容积占预计值百分比(FEV1% pred)及血清MMP-9等变化,并记录两组患者上1年及治疗后1年内急性发作及住院情况.结果 治疗前后实验组SGRQ评分、MMRC评分、6-MWD、PaO2、PaCO2、FEV1% pred、血清MMP-9分别是(63.60±3.92)分比(51.93±3.77)分、(3.65±0.48)分比(2.43±0.50)分、(158.85±6.39)m比(248.00±9.32)m、(56.98±1.63)mm Hg比(66.58±2.23)mm Hg、(60.58±2.89) mm Hg比(51.55±2.28) mm Hg、(38.68±3.17)比(42.05±3.11)、(182.85±6.62)μg/L比(170.93±6.51)μg/L,治疗前后对照组SGRQ评分、MMRC评分、6-MWD、PaO2、PaCO2、FEV1% pred、血清MMP-9分别是(64.40±4.33)分比(53.75±3.73)分、(3.73±0.45)分比(2.83±0.39)分、(156.50±5.88)m比(211.43±7.53)m、(56.80±1.57)mm Hg比(62.58±1.91) mm Hg、(59.90±3.49) mm Hg比(55.98±3.36)mm Hg、(38.85±2.77)比(40.80±3.16)、(180.60±5.23) μg/L比(172.83±5.22)μg/L,实验组改善优于对照组(P<0.05或P<0.01);急性发作次数、住院天数等明显减少,实验组优于对照组.结论 严重COPD合并呼吸衰竭患者稳定期长期NIPPV可明显提高患者生活质量,降低血清MMP-9水平.%Objective To investigate the clinical efficacy of the treatment with long-term NIPPV in patients with stable severe COPD complicated with respiratory failure,and the impacting on serum levels of MMP-9.Methods We selected prospectively 80 outpatients of stable severe COPD complicated with respiratory failure which were divided into two groups (experimental and control group,each group 40)according to their ability to tolerate and accept the long-term NIPPV treatment,two groups of patients were given oxygen therapy,slow-release oral theophylline,and inhalation of tiotropium for one year,and added to 1 year NIPPV therapy in experimental group.The outcomes measured included the followings:SGRQ score,MMRC score,6-MWD,PaO2,PaCO2,FEV1 %pred,the serum levels of MMP-9 and the rate of acute exacerbations of COPD and hospital days in last 1 year and following 12 months.Results After 1year,the differences of SGRQ score,MMRC score,6-MWD,PaO2,PaCO2,FEV1% pred,MMP-9 in the experimental group [(63.60 ± 3.92) scores vs (51.93 ± 3.77) scores,(3.65 ± 0.48) scores vs (2.43±0.50) scores,(158.85±6.39) mvs (248.00±9.32) m,(56.98±1.63) mm Hg vs (66.58±2.23) mm Hg,(60.58±2.89) mm Hg vs (51.55±2.28) mm Hg,(38.68±3.17) vs (42.05±3.11),(182.85±6.62) μg/L vs (170.93 ± 6.51) μg/L] were statistically significant compared to the control group [(64.40±4.33) scores vs (53.75±3.73) scores,(3.73± 0.45) scores vs (2.83±0.39) scores,(156.50±5.88) m vs (211.43±7.53) m,(56.80±1.57) mm Hg vs (62.58±1.91) mm Hg,(59.90±3.49) mm Hg vs (55.98±3.36) mm Hg,(38.85±2.77) vs (40.80±3.16),(180.60±5.23) μg/L vs(172.83±5.22) μg/L](all P <0.05 or P <0.01),the rate of acute exacerbations COPD and hospital days were decreased,and the experimental group excelled.Conclusions Our study indicates that longterm NIPPV could significantly improve the living conditions of the patients with severe stable COPD complicated with respiratory failure,lower the serum levels of MMP-9.